Evaluate the Efficacy and Safety of Combination Treatment With DW1501-R1+DW1501-R2 Versus DW1501-R1 or DW1501-R2+DW1501-R3 in Patients With Hypertension and Dyslipidemia

• Status: Completed
• Trial end date: 2017-09-01
• Target enrollment: 0
• Participant gender: All

Summary

A Multicenter, Randomized, Double-blinded, Double-dummy, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Treatment with DW1501-R1+DW1501-R2 Versus DW1501-R1 or DW1501-R2+DW1501-R3 in Patients with Hypertension and Dyslipidemia

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Daewon Pharmaceutical Co., Ltd.
• Treatments: Amlodipine; Rosuvastatin Calcium; Telmisartan; Telmisartan amlodipine combination

Criteria

Inclusion Criteria:

• Adults both male and female who are ≥19,<80 years old

• at screening, 140mmHg≤ SBP<180mmHg & 90mmHg≤ DBP<110mmHg & LDL-C≤250mg/dL & triglyceride<400mg/dL

Exclusion Criteria:

• at screening, the difference BP of one-side arm is SBP ≥ 20mmHg and DBP ≥ 10mmHg

• secondary hypertension or secondary dyslipidemia

• patients who have uncontrolled diabetes melitus, hyper/hypothyroidism or cardiac disease

• women who are pregnant or lactating